Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House Ways & Means staffers

This article was originally published in The Gray Sheet

Executive Summary

Former Boston Scientific lobbyist Allison Giles will serve as staff director for the full Ways & Means Committee. Giles was on the personal staff of Rep. Bill Thomas (R-Calif.) from 1994-96 and worked in Thomas' Ways & Means/Health Subcommittee staff from 1997-99 on elements of the 1997 Balanced Budget Act. Separately, John McManus, Rep. Thomas' chief health care policy advisor for the past three years, is named staff director for the Ways & Means/Health Subcommittee Feb. 1

You may also be interested in...



Prestige Expands UK Eye Care Range In Response To Consumer Demand

A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.

Who’s Hired? Hikma Recruits New US Generics President

A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.

Organon And Henlius Complete Phase III For Denosumab

Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT014443

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel